This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Medical Xpress - Cardiology
JANUARY 25, 2024
An international academic consortium has identified 13 biomarkers that significantly improve the ability to accurately predict cardiovascular disease risk in people with type 2 diabetes.
Physiologically Speaking
JULY 24, 2024
Andrew is a research scientist at Sansum Diabetes Research Institute, where he’s investigating metabolic therapies for health and disease. His mission is to optimize metabolic health and patient outcomes for people living with type 1 diabetes. Andrew is unique because he himself has type 1 diabetes.
115 
Becker's Hospital Review - Cardiology
JANUARY 3, 2024
Dallas-based UT Southwestern Medical Center researchers found a two-step screening protocol combining clinical risk assessment with biomarker testing that can identify which patients with Type 2 diabetes need medication to prevent heart failure.
110 
Frontiers in Cardiovascular Medicine
FEBRUARY 24, 2025
This results in severe chest pain or discomfort, with the subsequent release of cardiac biomarkers, and alterations in the electrocardiogram. Hypertension and diabetes were the two most common risk factors identified. It can cause diminished heart function and mortality if not treated properly with suitable measures.
98 
Cardiovascular Diabetology
MARCH 19, 2025
This study aims to identify early metabolomic biomarkers of gestational diabetes mellitus (GDM) and evaluate their association with hepatic steatosis.
52 
Science Daily - Heart Disease
MARCH 18, 2024
Coronary heart disease is a major global health problem, especially among people with type 2 diabetes. Researchers have identified novel protein biomarkers that are associated with the development of CHD in people with and without diabetes.
73 
HCPLive
JANUARY 29, 2024
A systematic review of over 400 studies in type 2 diabetes reveals 13 biomarkers, including NT-proBNP and troponin-t, with potential to significantly enhance cardiovascular disease risk prediction.
Medical Xpress - Cardiology
MARCH 18, 2024
Among middle-aged adults, individuals with type 2 diabetes (T2D) have a two to four times higher risk of developing CHD than people without T2D. The research team investigated the predictive performance of protein biomarkers on incident CHD in individuals with and without T2D.
75 
Medical Xpress - Cardiology
JANUARY 2, 2024
A two-step screening protocol that combines clinical risk assessment with biomarker testing can more effectively identify which patients with type 2 diabetes need medication to prevent heart failure, according to a study led by UT Southwestern Medical Center researchers.
Med Page Today
JUNE 23, 2024
(MedPage Today) -- ORLANDO -- An investigational triple-hormone receptor agonist improved metabolic profiles of people with obesity with or without type 2 diabetes, an exploratory biomarker analysis of a phase II trial found. After 36 weeks.
110 
Cardiovascular Diabetology
NOVEMBER 1, 2024
Dysglycemia and insulin resistance increase type 2 diabetes (T2D) and cardiovascular disease (CVD) risk, yet associations with specific glucose-insulin homeostatic biomarkers have been inconsistent. Vitamin D.
Cardiovascular Diabetology
DECEMBER 17, 2024
Diabetic retinopathy (DR) is a major microvascular complication of diabetes mellitus and causes vision impairment and blindness. The presence of major risk factors for DR, such as high levels of HbA1c, does no.
59 
Cardiovascular Diabetology
MARCH 7, 2025
Coronary artery disease (CAD) and diabetes mellitus (DM) can induce changes in myocardial structure and function, thereby increasing the risk of heart failure (HF). We aimed to identify the alterations in echo.
Cardiovascular Diabetology
OCTOBER 27, 2024
Systemic stress, inflammation, and hydroelectrolytic and acid‒base abnormalities observed during diabetic ketoacidosis (DKA) can cause changes in the heart and even induce cardiovascular damage. We aimed to ev.
52 
Cardiovascular Diabetology
JANUARY 19, 2024
Type 2 diabetes mellitus (T2DM) increases the risk of coronary heart disease (CHD) by 2–4 fold, and is associated with endothelial dysfunction, dyslipidaemia, insulin resistance, and chronic hyperglycaemia.
69 
Dr. Paddy Barrett
FEBRUARY 21, 2025
The reason excess weight is such big issues are the health consequences it confers with increased rates of diabetes, heart disease, osteoarthritis, obstructive sleep apnea, non-alcoholic fatty liver disease and others, just to name a few. Avoiding diabetes and its precursor states inclduing insulin resistance is key. Nat Med (2024).
77 
Cardiovascular Diabetology
MARCH 20, 2025
The triglyceride-glucose index serves as a dependable biomarker for gauging insulin resistance linked to cardiovascular disease. Our study was designed to investigate how the trajectory of the triglyceride-glu.
DAIC
MARCH 25, 2025
25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies." Additional ACC.25
Cardiovascular Diabetology
MAY 2, 2024
Type 2 Diabetes Mellitus (T2DM) presents a significant healthcare challenge, with considerable economic ramifications. While blood glucose management and long-term metabolic target setting for home care and ou.
52 
Cardiovascular Diabetology
APRIL 28, 2024
Glycemic control, as measured by glycosylated hemoglobin (HbA1c), is an important biomarker to evaluate diabetes severity and is believed to be associated with heart failure development. Type 2 diabetes mellit.
Cardiovascular Diabetology
AUGUST 6, 2024
Gestational diabetes mellitus (GDM) significantly impacts maternal and infant health both immediately and over the long term, yet effective early diagnostic biomarkers are currently lacking. Thus, it is essent.
52 
Cardiovascular Diabetology
JANUARY 12, 2025
Diabetic myocardial disorder (DbMD, evidenced by abnormal echocardiography or cardiac biomarkers) is a form of stage B heart failure (SBHF) at high risk for progression to overt HF. SBHF is defined by abnormal.
52 
Dr. Paddy Barrett
APRIL 26, 2024
On the far end of that line is type two diabetes. Insulin resistance and diabetes may not ‘ cause ’ coronary artery disease, but they are huge accelerants. Compared to someone without type 2 diabetes, the person with type 2 diabetes has a risk that is tenfold higher 1. Let me be 100% clear, however.
104 Circulation
MARCH 9, 2025
Albuminuriaincreased urine albumin excretionis associated with cardiovascular mortality among patients with diabetes, hypertension, chronic kidney disease, or heart failure, as well as among adults with few cardiovascular risk factors. Circulation, Volume 151, Issue 10 , Page 716-732, March 11, 2025.
DAIC
APRIL 9, 2024
The international ARISE-HF trial was designed to test the effectiveness of the investigational drug AT-001 at stabilizing exercise capacity in patients with diabetic cardiomyopathy. Patients had had Type 2 diabetes for an average of 14 years. Decline in exercise ability is a hallmark of progression to overt heart failure.
Stroke Journal
JANUARY 30, 2025
Studies have searched for biomarkers for CA to provide early and easy diagnosis of unruptured CA through blood transcriptome analysis; however, biomarkers from individual studies cannot be validated across studies due to sample size. We hypothesized that increasing CA sample size will allow more robust biomarker identification.
40 
DAIC
FEBRUARY 1, 2024
.** According to the American Diabetes Association, cardiovascular disease (CVD), where the heart and blood vessels are negatively impacted, is the number one cause of death in people living with diabetes, resulting in 2/3 of deaths in people with type 2 diabetes. million have diagnosed diabetes; and 9.7 In addition, 115.9
European Journal of Heart Failure
NOVEMBER 3, 2024
Development and validation of a machine-learning approach to identify diabetic cardiomyopathy. Aims Abnormalities in specific echocardiographic parameters and cardiac biomarkers have been reported among individuals with diabetes. The high-risk DbCM phenotype was identified based on the incidence of HF on follow-up.
Circulation: Genomic and Precision Medicine
FEBRUARY 7, 2024
BACKGROUND:The circulating proteome may encode early pathways of diabetes susceptibility in young adults for surveillance and intervention. kg/m2), with validation against diabetes in >1800 individuals in the FHS (Framingham Heart Study) and WHI (Women’s Health Initiative).RESULTS:In
40 
Cardiovascular Diabetology
FEBRUARY 12, 2024
Studies have demonstrated that coronary artery calcification on one hand and non-alcoholic fatty liver disease (NAFLD) on the other hand are strongly associated with cardiovascular events. However, it remains.
69 
Cardiovascular Diabetology
OCTOBER 13, 2024
Triglyceride (TG) and its related metabolic indices are recognized as important biomarker gauging cardiovascular diseases. This study aimed to explore the association between multiple TG-derived metabolic indi.
Stroke Journal
FEBRUARY 1, 2024
Diabetes doubles the risk of VCID. We showed that diabetic but not control rats develop a progressive cognitive decline in a microemboli (ME) model of VCID. Behavioral deficits observed in the untreated diabetic rats were not noted in the treated group. Some of the biomarkers were unchanged (Table).
40 
Circulation: Heart Failure
JANUARY 16, 2025
However, no biomarker reflecting RVD is available for routine clinical use.METHODS:Proteomic analysis of myocardium from the left ventricle and right ventricle (RV) of patients with heart failure with reduced ejection fraction with (n=10) and without RVD (n=10) who underwent heart transplantation was performed.
40 
Cardiovascular Diabetology
SEPTEMBER 27, 2024
The pericoronary fat attenuation index (FAI) has emerged as a novel and sensitive biomarker reflecting the degree of coronary artery inflammation. Semaglutide has been demonstrated to exert a cardiovascular pr.
52 
Stroke Journal
FEBRUARY 1, 2024
had diabetes mellitus, and 53.7% It also identifies a novel biomarker for ischemic strokes from atherosclerosis. The relationship between stroke etiology (TOAST criteria) and IL-2Rα was assessed using ANOVA and then adjusted for co-morbidities using multilinear regression models.Results:The mean age of patients was 63.4 p<0.01).Conclusions:Our
40 
Stroke Journal
JANUARY 30, 2025
years, 54% were women, 87% had hypertension, 44% had diabetes mellitus, and 54% had hyperlipidemia. Only two out of the 48 cytokines demonstrated differences with thrombectomy. CCL4 levels were significantly higher in patients that underwent thrombectomy, 55.717.4 pg/ml vs. 39.520.6
40 
Circulation
NOVEMBER 11, 2024
Background:Peripheral artery disease (PAD) is associated with high morbidity and mortality and is closely related to diabetes mellitus (DM) and atherosclerosis. These findings suggest that VTRNA2-1 promoter methylation status could serve as a valuable biomarker for predicting prognosis and guiding treatment strategies in PAD.
Dr. Paddy Barrett
SEPTEMBER 13, 2024
Everyone sits somewhere on the scale of insulin sensitivity from very insulin sensitive to very insulin resistant at the point of type 2 diabetes. When insulin resistance progresses to type 2 diabetes, that risk increases to a 10-fold increase in risk. Measuring Insulin Resistance. There are many ways to assess insulin resistance.
105 
Cardiometabolic Health Congress
JULY 25, 2024
Practical, Future-Focused Education Cardiorenal and metabolic diseases, fueled by poor lifestyle choices and health conditions, lead to type 2 diabetes, cardiovascular disease, and chronic kidney disease. The robust conference agenda begins with FDA updates and advancements in cardiorenal metabolic care.
100 
Heart BMJ
SEPTEMBER 25, 2024
Background Integration of large proteomics and genetic data in population-based studies can provide insights into discovery of novel biomarkers and potential therapeutic targets for cardiometabolic diseases (CMD). There were 245 potentially causal protein biomarkers identified in MR pooled results, involving 23 pleiotropic proteins.
52 
DAIC
MARCH 25, 2025
25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies." Additional ACC.25
Frontiers in Cardiovascular Medicine
FEBRUARY 20, 2024
Analysis of inflammatory biomarkers and coronary CTA was also performed at baseline and 4 weeks after treatment. Among those, 58% had diabetes, 50% had myocardial infarction, and 91% were in use of statin and aspirin. Clinical and laboratory safety evaluations were made at baseline and every 3 weeks until the end of the study.
Cardiometabolic Health Congress
AUGUST 8, 2024
Cardiometabolic risk encompasses a complex spectrum of interrelated conditions, including cardiovascular disease, type 2 diabetes, and metabolic syndrome. Key contributions: Advanced cardiac imaging (e.g., high-sensitivity troponin, NT-proBNP) in risk stratification Utilization of advanced echocardiographic techniques (e.g.,
59 
Heart BMJ
APRIL 15, 2024
Participants underwent clinical cardiovascular evaluation, ECG, cardiac biomarker evaluation and CMR. mmol/L and 5% had a new diagnosis of diabetes. All participants had normal LVEF prior to, and on completion of, treatment. Left ventricular systolic dysfunction (LVSD) was defined as LVEF <50%. years (range 5.9–10.8
52
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content